Laura A. Kerepesi, PhD, associate director – Preclinical Manufacturing, Andelyn Biosciences shares insight on the key learnings from 2022 within the C> sector, as well as upcoming 2023 trends around gene therapy.
What are the key learnings from 2022?
In the last year, the gene therapy space has continued to mature, with the number of gene therapies in the development pipeline rising steadily to a total of 2,031 and two new drug approvals globally. Our expanding understanding of genetics and advances in molecular engineering techniques has enabled gene therapies to branch out from the treatment of rare diseases into the more common indications, including various cancers and heart diseases.